Huadong Medicine Subsidiary Gains Approval for Clinical Trial of HDM2017 Injection

Huadong Medicine's Unit Gets Registration Certificate for V30 Skin Treatment System

Huadong Medicine Gets China Nod for Lymphoma Combo Trial

Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30

Mixed Performance: Huadong Medicine Navigates Innovation Realization and Sectoral Headwinds

Beneath the Surface of Huadong Medicine's Strong Figures: First Non-GAAP Profit Drop, High Receivables, and Cash Flow Strain

Chinese Drug Regulator Accepts Huadong Medicine's Application for Facial Filler's New Indication

Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance

Beyond Next Ventures leads SCOHIA PHARMA private funding round raising JPY 3 billion

Huadong Medicine's Subsidiary Gains NMPA Approval for Crohn's Disease Treatments

Huadong Medicine's Unit Gets Nod to Trial HDM2017 for Injection

Huadong Medicine's Attributable Profit Slips 2.8% in 2025

Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%

BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/Y

Huadong Medicine's Weight-Loss Drug Marketing Application Accepted in China

CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue

Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era

China Stocks Jump on Positive Industrial Profit Growth

Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial

Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial